Evotec AG (Evotec) is a drug discovery and development company focused on small molecule therapeutics. Evotec is developing treatments for diseases in the areas of neuroscience, pain, and inflammation. Evotec’s portfolio comprises five clinical drug candidates: EVT 101, a subtype selective NMDA receptor antagonist with potential for the treatment of Alzheimer’s disease, pain and depression, EVT 201, a partial positive allosteric modulator (pPAM) of the GABAA receptor complex for the treatment of insomnia, EVT 302, a MAO-B inhibitor in development for smoking cessation, a P2X7 antagonist for the treatment of inflammatory diseases, and a small molecule vanilloid receptor (VR1) antagonist for the treatment of pain in partnership with Pfizer. Evotec’s late stage preclinical research programs focus on EVT 103, a back-up compound to EVT 101, H3 antagonists for the treatment of cognitive disorders and/or sleep, as well as antagonists for the purinergic receptor P2X3 for the treatment of pain.

Althea Technologies provides services that help drug developers speed up the drug discovery and testing process, as well as reduce risks and costs associated with research and development efforts. Founded in 1998 by co-chairs Francois Ferre and Magda Marquet -- who hold Ph.D.s in molecular oncology and biochemical engineering -- the company assists in the development process from discovery through testing, regulatory support, and contract manufacturing stages. Services include gene expression analysis, protein production, and therapeutic and vaccine product manufacturing for clinical trials.

Essential Group, Inc. company was founded in 1994 and taken private in 2007. Essential Group (formerly AmericasDoctor) is helping medical researchers find a more advanced way to cure that bellyache. The company acts as a contract research organization (CRO) to handle everything needed in a clinical drug trial, including study design, patient recruitment, clinical monitoring, and writing up the findings. It conducts Phase I-IV trials in areas such as cardiology, gastroenterology, urology, and women's health through test sites across the US. Essential Group's primary clients are pharmaceutical and biotechnology companies.

Matrixx Initiatives, Inc., through its subsidiaries, engages in the development, production, marketing, and sale of over-the-counter (OTC) healthcare products. It offers Zicam Cold Remedy nasal pump, a homeopathic nasal gel that reduces the duration and severity of the common cold; Zicam Cold Remedy Swabs for consumers, who dislike nasal sprays; and Zicam Cold Remedy Chewables, Zicam Cold Remedy RapidMelts, Zicam Cold Remedy Oral Mist, Zicam Cold Remedy RapidMelts + Vitamin C, and Zicam Cold Remedy RapidMelts + Vitamin C and Echinacea, which are oral cold remedy products that deliver a dose of ionic zinc to the oral mucosa. The company also provides Zicam Allergy Relief, a homeopathic nasal gel formula to control allergy symptoms for sufferers of hay fever and upper respiratory allergies; Zicam Extreme Congestion Relief, a nasal gel for relief of nasal congestion and sinus pressure; and Zicam Sinus Relief that provides the benefit of the product with the aromatic strength of a cooling menthol/eucalyptus blend. In addition, it offers Zicam Cough Spray products to deliver cough relief and soothe throat irritation, including Zicam Cough Max, a liquid spray formulation that provides relief. Further, the company offers Zicam Multi-Symptom Cold and Flu Relief products, which utilize a spoon dosing delivery to provide relief of cold and flu symptoms; and Xcid, a creamy antacid product. It sells products directly to food, drug, mass market, and wholesale warehouse retailers in the United States, as well as to distributors that sell to retail establishments under the Zicam, Nasal Comfort, and Xcid brands.

U.S. Genomics, Inc. company has developed the GeneEngine, a DNA sequencer that mimics natural cell division, rapidly reading and copying DNA. It is developing the technology to quickly detect and identify infectious pathogens and biomarkers for biodefense and diagnostic use. Its products can detect and quantify molecules of DNA, RNA, and proteins without amplification. Backed by private equity investors and biomedical firms including Becton Dickinson, U.S. Genomics has netted contracts with the Department of Homeland Security. Northrup Gruman is the company's bio-security development partner.

Fulcrum Pharma plc is a United Kingdom-based company. The Company is engaged in providing solutions for the development of therapeutic products. It provides regulatory expertise and resource throughout all stages of product development. The Company provides customized pharmacovigilance and risk management solutions. It provides support for product registration, launch and in market maintenance. It operates through eight offices across the United States, Europe and Japan. The Company’s subsidiaries include Fulcrum Pharma (Europe) Limited, Fulcrum Pharma Developments Limited, Quadramed Limited, Unicus Limited and Fulcrum Regulatory Limited.

Par Pharmaceutical Companies, Inc. was founded in 1978 and is based in Woodcliff Lake, New Jersey. Par Pharmaceutical Companies, Inc., through its subsidiary, Par Pharmaceutical, Inc. develops, manufactures, and distributes generic and branded pharmaceuticals drugs in the United States. Its principal generic products include Metoprolol succinate ER, Fluticasone, Meclizine Hydrochloride, Cabergoline, Sumatriptan succinate injection, Propranolol HCl ER, amoxicillin products, Dronabinol, Ibuprofen Rx, Megestrol oral suspension, Methimazole, Fluoxetine, Lovastatin, Tramadol HCl and acetaminophen tablets, Ranitidine HCl Syrup, Quinapril, and Cefprozil. The company offers its drugs in the solid oral dosage form, such as tablets, caplets, and two-piece hard-shell capsules, as well as oral suspension products and certain products in the semi-solid form of a cream.It markets its products to wholesalers, drug store chains, supermarket chains, mass merchandisers, distributors, managed health care organizations, mail order accounts, drug distributors, clinics, and government agencies. The company's brand products include Megace ES drugs for the treatment of anorexia, cachexia, or any unexplained significant weight loss in patients with a diagnosis of AIDS; and NanoCrystal Dispersion for megestrol acetate oral suspension. It has a joint venture with Rhodes Technology to research, develop, commercialize, and market pharmaceutical preparations for human therapy; a license and commercialization agreement with Intellipharmaceutics Corp. for the development of Dexmethylphenidate XR; and a development and supply agreement with Cipla Limited for the development of one generic product. The company has a collaboration agreement with Actavis Group for the development of 4 extended release generic products, such as Nifedipine XR, Methylphenidate LA, Zolpidem CR, and Alfuzosin.

Arrow Therapeutics was founded in 1998; AstraZeneca acquired the firm in 2007. Arrow Therapeutics is a pharmaceutical product discovery company that is researching new anti-infective medicines. The company's top candidate is RSV604, an antiviral molecular program to combat respiratory syncytial virus (RSV), a leading cause of respiratory infections worldwide. This candidate is currently undergoing clinical trials and has been licensed to Novartis. Other leading programs include compounds developed to fight infectious dieseases such as Hepatitis C, herpes, and chicken pox.

Sanofi Pasteur helps you guard against getting sick in the first place. The company is the US vaccines division of French drugmaker Sanofi-Aventis. It makes vaccines that protect against such infectious diseases as influenza, polio, and meningitis. Some of its top sellers are flu vaccines, childhood combination vaccines, and adult booster shots. It also makes travelers' vaccines that keep globetrotters safe from typhoid, cholera, yellow fever, and the like. Projects in development include improved vaccines for influenza, preventative vaccines for HIV and dengue fever, and therapeutic vaccines for cancer.

Diagnostic HYBRIDS was founded in 1983 by Ohio University professors and private investor and entrepreneur Dr. Wilfred Konneker. It has agreed to be acquired by Quidel for $130 million. Diagnostic HYBRIDS will tell you which kind you have. The company develops and markets cell culture kits to help identify various viruses and endocrine diseases. Its product line include kits to detect a wide range of influenza viruses, herpes simplex viruses 1 and 2, Chlamydia and Cytomegalovirus, which includes the viruses that cause chicken pox and mononucleosis. Other kits demonstrate thyroid functioning. The biotech firm also develops and sells cell-based detection products.

Inviting Real Estate Agents, Job Placements Agents, Educational Institutes, Software Service Providers, Real Estate Builders, Marriage Bureaus, Travel Agents, Restaurant Owners, Health & Fitness Centers and other Local Businesses to Post a FREE Classified Advertisement on Cootera.com Classifieds Website.